When Cadrenal Therapeutics, Inc. reports, what it reported each quarter, and how the stock took the results.
19 quarters. Mar 31, 2022 to Sep 30, 2026. mixed units.
Mar 30, before the open
Tue, Mar 30, 2027in 129 days
Projected from its last 8 releases. The company has not named the day yet.
| Period | Ended | Announced | Filed | Lag | Form | Revenue | Δ yoy | EPS dil. | Move | Source trail |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2026 | ||||||||||
| Q3 2026 | ||||||||||
Cadrenal Therapeutics, Inc. · CIK 1937993 · Engraved from SEC EDGAR
| Sep 30, 2026 |
| — |
| Nov 16, 2026 |
| 47 d |
| 10-Q |
| — |
| — |
| -$0.31 |
| — |
| Q2 2026 | Jun 30, 2026 | Aug 13, 2026 · after-hours | Aug 13, 2026 | 44 d | 10-Q | — | — | -$1.14 | 0.0% |
|---|
| Q1 2026 | Mar 31, 2026 | May 7, 2026 · pre-market | May 7, 2026 | 37 d | 10-Q | — | — | -$1.04 | +1.6% |
|---|
| FY 2025 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Q4 2025derived | Dec 31, 2025 | Mar 31, 2026 · pre-market | Mar 31, 2026 | 90 d | 10-K | — | — | — | +20.8% | |
| Q3 2025 | Sep 30, 2025 | Nov 10, 2025 · pre-market | Nov 10, 2025 | 41 d | 10-Q | — | — | -$1.31 | 5.9% | |
| Q2 2025 | Jun 30, 2025 | Aug 11, 2025 · after-hours | Aug 11, 2025 | 42 d | 10-Q | — | — | -$1.87 | +2.1% | |
| Q1 2025 | Mar 31, 2025 | May 8, 2025 · after-hours | May 8, 2025 | 38 d | 10-Q | — | — | -$2.09 | 1.6% | |
| FY 2024 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Q4 2024derived | Dec 31, 2024 | Mar 13, 2025 · after-hours | Mar 13, 2025 | 72 d | 10-K | — | — | — | +13.4% | |
| Q3 2024 | Sep 30, 2024 | Nov 7, 2024 · pre-market | Nov 7, 2024 | 38 d | 10-Q | — | — | -$2.18 | +10.1% | |
| Q2 2024 | Jun 30, 2024 | — | Aug 7, 2024 | 38 d | 10-Q | — | — | -$2.24 | +2.4% | |
| Q1 2024 | Mar 31, 2024 | — | May 9, 2024 | 39 d | 10-Q | — | — | -$1.56 | — | |
| FY 2023 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Q4 2023derived | Dec 31, 2023 | Mar 11, 2024 · pre-market | Mar 11, 2024 | 71 d | 10-K | — | — | — | — | |
| Q3 2023 | Sep 30, 2023 | Nov 9, 2023 · pre-market | Nov 9, 2023 | 40 d | 10-Q | — | — | -$1.01 | 4.3% | |
| Q2 2023 | Jun 30, 2023 | Aug 10, 2023 · pre-market | Aug 10, 2023 | 41 d | 10-Q | — | — | -$0.09 | — | |
| Q1 2023 | Mar 31, 2023 | May 10, 2023 · pre-market | May 10, 2023 | 40 d | 10-Q | — | — | -$0.48 | 3.4% | |
| FY 2022 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Q4 2022derived | Dec 31, 2022 | — | Mar 30, 2023 | 89 d | 10-K | — | — | — | +5.3% | |
| Q3 2022 | Sep 30, 2022 | — | — | — | — | — | — | -$0.13 | — | |
| Q2 2022 | Jun 30, 2022 | — | — | — | — | — | — | $0.07 | — | |
| Q1 2022 | Mar 31, 2022 | — | — | — | — | — | — | -$0.02 | — | |
Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.
The stock’s move from the last close before each release to the first close after it, over the last 12 releases. Largest: +20.8% after Q4 2025.
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.